Literature DB >> 20978370

DNA methylation changes associated with cancer risk factors and blood levels of vitamin metabolites in a prospective study.

Paolo Vineis1, Shu-Chun Chuang, Thomas Vaissière, Cyrille Cuenin, Fulvio Ricceri, Mattias Johansson, Per Ueland, Paul Brennan, Zdenko Herceg.   

Abstract

Aberrant DNA methylation is a major epigenetic mechanism of gene silencing in a wide range of human cancers. Previous studies on DNA methylation typically used paired tumor and normal-appearing surrounding tissues from cancer-bearing individuals. However, genomic DNA isolated from surrogate tissues such as blood cells represents an attractive material that can be exploited in the discovery of biomarkers of exposure and tumorigenesis. Here we examined the association between lung cancer and DNA methylation patterns in a panel of candidate genes. We also investigated whether blood levels of vitamin metabolites modify DNA methylation levels in blood cells. To this end, we quantitatively determined DNA methylation levels in blood cells of nested cases and controls from a prospective study with well defined dietary habits and lifestyles. Multiple CpG sites in five genes (CDKN2A/p16, RASSF1A, GSTP1, MTHFR, and MGMT) that are frequent targets of hypermethylation in a variety of human malignancies were included in the analysis. While no clear association between DNA methylation patterns and the case/control status was found, with the exception of RASSF1A hypermethylation, methylation level changed according to serum levels of 1-carbon metabolites and vitamins B. Overall, folate was associated with increased methylation levels of RASSF1A and MTHFR and methionine was associated with decreased methylation levels of RASSF1A. The associations with folate were more pronounced among never smokers while the associations with methionine were more evident among ever-smokers. These results are consistent with the notion that blood levels of 1-carbon metabolism markers and dietary/lifestyle factors may modify DNA methylation levels in blood cells and that blood cells can be exploited for the discovery of epigenetic biomarkers of exposures, providing proof-of-principle on the use of blood samples in the context of prospective studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20978370     DOI: 10.4161/epi.6.2.13573

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  23 in total

1.  Sex-specific association of sequence variants in CBS and MTRR with risk for promoter hypermethylation in the lung epithelium of smokers.

Authors:  Kristina G Flores; Christine A Stidley; Amanda J Mackey; Maria A Picchi; Sally P Stabler; Jill M Siegfried; Tim Byers; Marianne Berwick; Steven A Belinsky; Shuguang Leng
Journal:  Carcinogenesis       Date:  2012-06-04       Impact factor: 4.944

Review 2.  Epigenetic Signatures as Biomarkers of Exposure.

Authors:  Christine Ladd-Acosta
Journal:  Curr Environ Health Rep       Date:  2015-06

Review 3.  Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation.

Authors:  Olivia S Anderson; Karilyn E Sant; Dana C Dolinoy
Journal:  J Nutr Biochem       Date:  2012-06-27       Impact factor: 6.048

4.  Serum betaine but not choline is inversely associated with breast cancer risk: a case-control study in China.

Authors:  Yu-Feng Du; Fang-Yu Lin; Wei-Qing Long; Wei-Ping Luo; Bo Yan; Ming Xu; Xiong-Fei Mo; Cai-Xia Zhang
Journal:  Eur J Nutr       Date:  2016-02-20       Impact factor: 5.614

5.  A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk.

Authors:  Valéria Troncoso Baltar; Wei W Xun; Mattias Johansson; Pietro Ferrari; Shu-Chun Chuang; Caroline Relton; Per Magne Ueland; Øivind Midttun; Nadia Slimani; Mazda Jenab; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Guy Fagherazzi; Rudolf Kaaks; Sabine Rohrmann; Heiner Boeing; Cornelia Weikert; Bas Bueno-de-Mesquita; Hendriek Boshuizen; Carla H van Gils; N Charlotte Onland-Moret; Antonio Agudo; Aurelio Barricarte; Carmen Navarro; Laudina Rodríguez; José Maria Huerta Castaño; Nerea Larrañaga; Kay-Tee Khaw; Nick Wareham; Naomi E Allen; Francesca Crowe; Valentina Gallo; Teresa Norat; Vittorio Krogh; Giovanna Masala; Salvatore Panico; Carlotta Sacerdote; Rosario Tumino; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Torgny Rasmuson; Göran Hallmans; Nina Roswall; Anne Tjønneland; Elio Riboli; Paul Brennan; Paolo Vineis
Journal:  Eur J Epidemiol       Date:  2013-03-27       Impact factor: 8.082

Review 6.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

7.  DNA methylation variant, B-vitamins intake and longitudinal change in body mass index.

Authors:  Xiang Li; Tiange Wang; Min Zhao; Tao Huang; Dianjianyi Sun; Liyuan Han; Hoirun Nisa; Xiaoyun Shang; Yoriko Heianza; Lu Qi
Journal:  Int J Obes (Lond)       Date:  2018-05-17       Impact factor: 5.095

8.  Tumor suppressor genes are differentially regulated with dietary folate modulations in a rat model of hepatocellular carcinoma.

Authors:  Renuka Sharma; Taqveema Ali; Jyotdeep Kaur
Journal:  Mol Cell Biochem       Date:  2020-09-24       Impact factor: 3.396

9.  Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population.

Authors:  Chikako Kiyohara; Takahiko Horiuchi; Koichi Takayama; Yoichi Nakanishi
Journal:  BMC Cancer       Date:  2011-10-25       Impact factor: 4.430

10.  The role of longitudinal cohort studies in epigenetic epidemiology: challenges and opportunities.

Authors:  Jane W Y Ng; Laura M Barrett; Andrew Wong; Diana Kuh; George Davey Smith; Caroline L Relton
Journal:  Genome Biol       Date:  2012-06-29       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.